Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 7, 1998, Pages 715-720

  Rodgers, James D ^a   Johnson, Barry L ^a   Wang, Haisheng ^a   Erickson Viitanen, Susan ^a   Klabe, Ronald M ^a   Bacheler, Lee ^a   Cordova, Beverly C ^a   Chang, Chong Hwan ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOINDAZOLE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; INDAZOLES; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032492679     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00118-8     Document Type: Article

References (20)

1. 1. For reviews see: (a) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Drug Discovery Today 1997, 2, 6.
2. (b) Chrusciel, R. A. Exp. Opin. Ther. Patents. 1997, 7, 111.
3. (c) De Clercq, E. J. Med. Chem. 1995, 14, 2491.
4. (d) West, M. L.; Fairlie, D. P. Trends Pharmacol Sci. 1995,16, 67.
5. (e) Thaisrivongs, S. Annu. Rep. Med. Chem. 1994, 29, 133.
6. (f) Wlodawer, A.; Erickson, J. W. Annu. Rev. Biochem. 1993, 62, 543.
7. (g) Martin, J. A. Antiviral Res. 1992, 17, 265.
8. (h) Meek, T. D. J. Enzyme Inhib. 1992, 6, 65.
9. (i) Huff, J. R. J. Med. Chem. 1991, 34, 2305.
10. 2. (a) Vacca, J. P.; Condra, J. H. Drug Discovery Today 1997, 2, 261.
11. (b) Danner, S. A.; Carr, A.; Leonard, J. M.; Leman, L. M.; Gudiol, F.; Gonzales, J.; Raventos, A.; Rubio, R.; Bouza, E.; Pintado, V.; Aguado, A. G.; De Lomas, J. G.; Delgado, R.; Borleffs, J. C. C.; Hsu, A.; Valdes, J. M.; Boucher, C. A. B.; Cooper, D. A. N. Engl. J. Med. 1995, 333, 1528.
12. (c) Markowitz, M.; Saag, M.; Powderly, W. G.; Hurley, A. M.; Hsu, A.; Valdes, J. M.; Henry, D.; Sattler, F.; La Marca, A.; Leonard, J. M.; Ho, D. D. N. Eng. J. Med. 1995, 333, 1534.
13. (d) Kitchen. V. S.; Skinner, C.; Ariyoshi, K.; Lane, E. A.; Duncan, I. B.; Burckhardt, J.; Burger, H. U.; Bragman, K.; Pinching, A. J.; Weber, J. N. The Lancet 1995, 345, 952.
14. 3. Rodgers, J. D.; Johnson, B. L.; Wang, H.; Greenberg, R. A.; Erickson-Viitanen, S.; Klabe, R. M.; Cordova, B. C.; Rayner, M. M.; Lam, G. N.; Chang, C.-H. Bioorg. Med. Chem. Lett. 1996, 6, 2919.
15. 4. Solubility was determined by reverse phase HPLC on filtrates of saturated solutions at pH 7.4.
16. 5. Pierce, M. E.; Harris, G. D.; Islam, Q.; Radesca, L. A.; Storace, L.; Waltermire, R. E.; Wat, E.; Jadhav, P. K.; Emmett, G. C. J. Org. Chem. 1996, 61, 444.
17. 6. Katritzky, A. R.; Stanislaw, R.; Hitchings, G. J. Tetrahedron 1991, 47, 2683.
18. i's were measured (n = 2) by assaying the cleavage of a fluorescent peptide substate using HPLC. Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Antimicro. Agents Chemother. 1994, 38, 1628.
19. 8. Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C.-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. J. Med. Chem. 1991, 40, 181.
20. 90's were determined (n = 2) by measuring the accumulation of viral RNA transcripts three days after infection of MT-2 cells with HIV-1 RF. Bachelor, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. Antiviral Chem. Chemother. 1994, 5, 111.